Palisade Bio (PALI) Change in Intangibles (2010 - 2017)
Palisade Bio (PALI) reported Change in Intangibles of -$1129.0 for Q3 2017, down 103.44% on a QoQ basis from $32843.0 in Q4 2016.
Palisade Bio (PALI) has 8 years of Change in Intangibles data on file, last reported at -$1129.0 in Q3 2017.
- Quarterly Change in Intangibles changed N/A year-over-year to -$1129.0 in Q3 2017, while the trailing twelve-month figure through Dec 2017 was $31714.0 (down 49.68% YoY) and the FY2017 annual result came in at $82645.0, up 31.13% from the prior year.
- Change in Intangibles fell to -$1129.0 in Q3 2017 per PALI's latest filing, from $32843.0 in the prior quarter.
- Across five years, Change in Intangibles topped out at $137054.0 in Q2 2013 and bottomed at -$8823.0 in Q3 2015.
- The 5-year median for Change in Intangibles is $48801.0 (2014), against an average of $55584.5.
- The widest annual swing landed in 2015, when Change in Intangibles tumbled 114.58%; it then soared 457.13% in 2016.
- Tracing PALI's Change in Intangibles over 5 years: stood at $85905.0 in 2013, then slumped by 53.07% to $40319.0 in 2014, then sank by 85.38% to $5895.0 in 2015, then soared by 457.13% to $32843.0 in 2016, then plunged by 103.44% to -$1129.0 in 2017.
- Per Business Quant, the three latest PALI Change in Intangibles figures stand at -$1129.0 (Q3 2017), $32843.0 (Q4 2016), and $17436.0 (Q2 2016).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 68,980.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | -1,129.00 |
| Sep 30, 2017 | -1,129.00 |
| Dec 31, 2016 | 32,843.00 |
| Dec 31, 2016 | 32,843.00 |
| Jun 30, 2016 | 17,436.00 |
| Jun 30, 2016 | 17,436.00 |
| Mar 31, 2016 | 12,747.00 |
| Mar 31, 2016 | 12,747.00 |
| Dec 31, 2015 | 5,895.00 |
| Dec 31, 2015 | 5,895.00 |
| Sep 30, 2015 | -8,823.00 |
| Sep 30, 2015 | -8,823.00 |
| Jun 30, 2015 | 12,957.00 |
| Jun 30, 2015 | 12,957.00 |
| Mar 31, 2015 | 57,283.00 |
| Mar 31, 2015 | 57,283.00 |
| Dec 31, 2014 | 40,319.00 |
| Dec 31, 2014 | 40,319.00 |
| Sep 30, 2014 | 60,534.00 |
| Sep 30, 2014 | 60,534.00 |
| Jun 30, 2014 | 135,534.00 |
| Jun 30, 2014 | 135,534.00 |
| Mar 31, 2014 | 112,068.00 |
| Mar 31, 2014 | 112,068.00 |
| Dec 31, 2013 | 85,905.00 |
| Dec 31, 2013 | 85,905.00 |
| Sep 30, 2013 | 93,568.00 |
| Sep 30, 2013 | 93,568.00 |
| Jun 30, 2013 | 137,054.00 |
| Jun 30, 2013 | 137,054.00 |
| Mar 31, 2013 | 95,161.00 |
| Mar 31, 2013 | 95,161.00 |
| Dec 31, 2012 | 57,523.00 |
| Dec 31, 2012 | 57,523.00 |
| Sep 30, 2012 | 38,033.00 |
| Sep 30, 2012 | 38,033.00 |
| Jun 30, 2012 | 91,314.00 |
| Jun 30, 2012 | 91,314.00 |
| Mar 31, 2012 | 28,768.00 |
| Mar 31, 2012 | 28,768.00 |
| Dec 31, 2011 | 51,470.00 |
| Dec 31, 2011 | 51,470.00 |
| Sep 30, 2011 | 127,303.00 |
| Sep 30, 2011 | 127,303.00 |
| Jun 30, 2011 | 61,146.00 |
| Jun 30, 2011 | 61,146.00 |
| Mar 31, 2011 | 44,519.00 |
| Mar 31, 2011 | 44,519.00 |
| Dec 31, 2010 | 77,450.00 |
| Dec 31, 2010 | 77,450.00 |
| Sep 30, 2010 | 86,410.00 |
| Sep 30, 2010 | 86,410.00 |